Dr. Michael Karin is a Distinguished Professor in the Department of Pharmacology at the University of San Diego (UCSD).
Dr. Karin performed groundbreaking work regarding the role of chronic inflammation in tumor development and demonstrated how certain outside factors can regulate innate immune activity and inflammation. For these contributions, he was awarded the 2013 William B. Coley Award, and has been elected to the National Academy of Sciences. His current research remains devoted to understanding the molecular mechanisms of inflammation with the goal of using cancer immunotherapy to defuse its effects and improve outcomes in patients. Dr. Karin is a member of CRI’s Scientific Advisory Council.
By defining factors that allow liver cells to progress from pre-cancer to cancer, we were able to find one that we can also use to predict a liver cancer patient's outcome following full removal of a previous liver tumor.
Let's spread the word about Immunotherapy! Click to share this page with your community.